Axonics Modulation Technologies Inc logo

AXNX - Axonics Modulation Technologies Inc Share Price

$31.63 -0.2  -0.7%

Last Trade - 4:05pm

Sector
Healthcare
Size
Mid Cap
Market Cap £829.2m
Enterprise Value £770.8m
Revenue £3.35m
Position in Universe 2393rd / 6416
Bullish
Bearish
Unlock AXNX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AXNX Revenue Unlock AXNX Revenue

Net Income

AXNX Net Income Unlock AXNX Revenue

Normalised EPS

AXNX Normalised EPS Unlock AXNX Revenue

PE Ratio Range

AXNX PE Ratio Range Unlock AXNX Revenue

Dividend Yield Range

AXNX Dividend Yield Range Unlock AXNX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AXNX EPS Forecasts Unlock AXNX Revenue
Profile Summary

Axonics Modulation Technologies, Inc. is a medical technology company. The Company is focused on the design, development, and commercialization of sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Its rechargeable SNM system (r-SNM System) delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. It has two clinical studies relating to its r-SNM System: a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. SNM therapy consists of two phases: an evaluation period, also called the external trial period, which typically lasts a few days to a few weeks, and a permanent implant for those patients who experience a successful external trial period.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated March 2, 2012
Public Since October 31, 2018
No. of Shareholders: n/a
No. of Employees: 87
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 33,978,911
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AXNX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AXNX
Upcoming Events for AXNX
Similar to AXNX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.